Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02483247
Title A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Boston Biomedical, Inc
Indications

Advanced Solid Tumor

Therapies

Paclitaxel

Doxorubicin

Capecitabine

Nivolumab

Sunitinib

Pembrolizumab

BBI503

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.